Results of the multicenter early feasibility study (EFS) of the Renata Minima stent as treatment for branch pulmonary artery stenosis and coarctation of aorta in infants
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31074 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Darren P Berman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute, Children's Hospital Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Feasibility Studies, Aortic Coarctation, Stents, Prosthesis Design. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Stent implantation has become standard of care in older children and adults for treatment of branch pulmonary artery stenosis (BPAS) and coarctation aorta (CoAo). There are no stents approved or available for infants that have the potential to be dilated to adult diameters. The Minima stent was designed to fulfill this unmet need.
Methods
Multicenter, prospective, nonrandomized early feasibility study evaluating safety and effectiveness of the Minima stent for treatment of BPAS and CoAo. Primary endpoints included: (1) successful deployment across lesion, (2) stenosis relief defined by an increase in angiographic diameter of >50% and (3) freedom from stent explant, embolization or migration at 30 days and 6 months.
Results
Between 2/2022 and 5/2022, 10 pts underwent Minima stent implantation with a median age and weight of 9 months (4–43 months) and 7.6 kg (5.1−16.9 kg). Procedural success and predefined stenosis relief was achieved in all cases (CoAo [ n = 4], BPAS [ n = 6]). Adverse events occurred in 3 pts: transient diminished lower extremity pulse ( n = 2), distal stent on‐balloon displacement successfully managed in the catheterization suite ( n = 1). There were no deaths or major adverse events. All patients were free from stent explant and migration at 30 days and 6 months with no evidence for significant restenosis at latest follow‐up.
Conclusions
Implantation of the Renata Minima stent was safe and effective for the treatment of BPAS and CoAo in this small cohort of infants and young children during early follow‐up. Based on these early results, an expanded study with longer follow‐up is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heart Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, Washington, USA.
- Department of Pediatrics, Heart Institute, Cincinnati Children's Hospital University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Smidt Heart Institute and Guerin Children's, Cedars Sinai Medical Center, Los Angeles, California, USA.
ORCID-Profile: Darren P Berman, Brian Morray, Evan M Zahn
Zitieren
APA
Berman, D. P., Morray, B., Sullivan, P., Shahanavaz, S., & Zahn, E. M. (2024). Results of the multicenter early feasibility study (EFS) of the Renata Minima stent as treatment for branch pulmonary artery stenosis and coarctation of aorta in infants. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31074
Vancouver
Berman DP, Morray B, Sullivan P, Shahanavaz S, Zahn EM. Results of the multicenter early feasibility study (EFS) of the Renata Minima stent as treatment for branch pulmonary artery stenosis and coarctation of aorta in infants. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31074
BibTeX
@article{Berman2024,
author = {Berman, Darren P and Morray, Brian and Sullivan, Patrick and Shahanavaz, Shabana and Zahn, Evan M},
title = {Results of the multicenter early feasibility study (EFS) of the Renata Minima stent as treatment for branch pulmonary artery stenosis and coarctation of aorta in infants},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31074}
}
EUVIMED